OPT (Opthea) Gross-Profit-to-Asset % : 0.03% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Opthea Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Opthea's annualized Gross Profit for the quarter that ended in Dec. 2024 was $0.05 Mil. Opthea's average Total Assets over the quarter that ended in Dec. 2024 was $167.28 Mil. Therefore, Opthea's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.03%.

Opthea Gross-Profit-to-Asset % Historical Data

The historical data trend for Opthea's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Gross-Profit-to-Asset % Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-0.59

-0.38

-0.04

-0.07

0.09

Opthea Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-0.06	-0.04	0.09	0.07	0.03

Competitive Comparison of Opthea's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Opthea's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Opthea's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Opthea Gross-Profit-to-Asset % Calculation

Opthea's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2024 )	/	( (Total Assets (A: Jun. 2023 )	+	Total Assets (A: Jun. 2024 ))	/ count )
	=	0.125	/	( (98.641	+	188.791)	/ 2 )
	=	0.125	/	143.716
	=	0.09 %

Opthea's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0.048	/	( (188.791	+	145.77)	/ 2 )
	=	0.048	/	167.2805
	=	0.03 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Opthea Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Opthea's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (NAS:OPT) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

UKJ:Germany OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.